Tenaya raises $52.5m to advance gene therapies for heart disease

Longevity.Technology is growing fast; we are open to conversations with prospective partners and investors who share our vision.

Please get in touch if you are interested:

Public offering supports trials of gene therapies targeting hypertrophic cardiomyopathy and arrhythmogenic right ventricular cardiomyopathy.

Heart disease focused biotech Tenaya Therapeutics has announced the pricing of its public offering of 75 million new shares, expected to generate approximately $52.5 million in gross proceeds. Shares in the company fell sharply on the news, as it plans to allocate the net proceeds toward the advancement of clinical stage gene therapy candidates, TN-201 and TN-401.

Create a free account to read this article now

Join the 12,000+ biotech, pharma and investment leaders who read Longevity.Technology. No password, no payment.

By continuing you agree to our Terms and Privacy Policy, and to receive the free Longevity.Technology newsletter. You can unsubscribe at any time.

Danny Sullivan

Danny has worked in technology communications for more than 20 years, and has been writing about developments the longevity sector since 2019. With a keen interest in the transfer of technology to market, he focuses primarily on the companies working on cutting-edge solutions to aging and age-related diseases.

Sign up for our daily newsletter to get our biggest longevity stories, handpicked for you each day.

Beauty giant and supplement startup both chase skin aging

The latest longevity science, investment, innovation and insight, delivered every morning.

Unlock Longevity Biotech Report for FREE